secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001558370-24-014760
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726
--------------------------------------------------------------------------------

- Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.
- Cash at Sept 30, 2024: $21.7M; expected to fund operations into Q3 2025.
- Positive top-line data from SAD Part 1 of Phase 1 trial for DA-1726: safe, tolerable, dose-linear PK; additional cohorts exploring MTD.
- DA-1241 Phase 2a MASH trial: top-line data expected in December 2024.
- Entered joint research agreement with Dong-A ST and ImmunoForge for once-monthly formulation of DA-1726.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/0001558370-24-014760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024014760/nrbo-20241107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer